Enlaza Therapeutics Secures $100M in Series A Funding
May 3, 2024, 3:32 pm
Location: United States, California, San Diego
Employees: 11-50
Total raised: $161M
Enlaza Therapeutics, a La Jolla-based company specializing in protein drugs, has successfully raised $100M in a Series A financing round. The funding was spearheaded by the Life Sciences Group of J.P. Morgan Private Capital, with support from existing investors Frazier Life Sciences, Avalon Ventures, Lightspeed Venture Partners, and Samsara BioCapital, as well as new investors like Amgen Ventures, Regeneron Ventures, Bregua Corporation, Pappas Capital, and Alexandria Venture Investments.
Enlaza Therapeutics, under the leadership of CEO Sergio Duron, is revolutionizing the field of covalent biologics through their proprietary platform called War-LockTM. This innovative technology allows for the creation of highly specific therapeutic warheads that covalently bind to targeted drug receptors, enhancing efficacy while minimizing peripheral exposure-related toxicities.
The company's Board of Directors, which includes key figures like Stephen Squinto, Ph.D., and Jamie Topper, M.D., Ph.D., is dedicated to advancing Enlaza Therapeutics' mission of developing a diverse pipeline of covalent protein drugs with significant clinical potential.
With this substantial funding, Enlaza Therapeutics plans to further develop their covalent protein technologies and advance their pipeline programs towards clinical trials. This financial support will play a crucial role in expanding the company's reach and solidifying its position as a leader in the biopharmaceutical industry.
Enlaza Therapeutics' success in securing $100M in Series A funding is a testament to the promising future of covalent biologics and the company's commitment to innovation and excellence in drug development.
Enlaza Therapeutics, under the leadership of CEO Sergio Duron, is revolutionizing the field of covalent biologics through their proprietary platform called War-LockTM. This innovative technology allows for the creation of highly specific therapeutic warheads that covalently bind to targeted drug receptors, enhancing efficacy while minimizing peripheral exposure-related toxicities.
The company's Board of Directors, which includes key figures like Stephen Squinto, Ph.D., and Jamie Topper, M.D., Ph.D., is dedicated to advancing Enlaza Therapeutics' mission of developing a diverse pipeline of covalent protein drugs with significant clinical potential.
With this substantial funding, Enlaza Therapeutics plans to further develop their covalent protein technologies and advance their pipeline programs towards clinical trials. This financial support will play a crucial role in expanding the company's reach and solidifying its position as a leader in the biopharmaceutical industry.
Enlaza Therapeutics' success in securing $100M in Series A funding is a testament to the promising future of covalent biologics and the company's commitment to innovation and excellence in drug development.